Overview

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients

Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine the safety and IOP-lowering ability of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Alcon Research
Treatments:
Latanoprost
Ophthalmic Solutions
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

- 18 years or older.

- Diagnosis of open-angle glaucoma or ocular hypertension.

- LogMAR visual acuity not worse than 0.6.

- Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

- Clinically relevant ophthalmic or systemic conditions.

- Other protocol-defined exclusion criteria may apply.